Metabolic syndrome and type 2 diabetes mellitus are individually associated with increased cardiovascular risk; furthermore, the combination of metabolic syndrome with diabetes accentuates this risk. An atherogenic dysli...
The microvascular complications of diabetes mellitus confer substantial morbidity and impair patient quality of life. Dyslipidemia and prolonged hyperglycemia promote an increase in oxidative stress, inflammation, and va...
Patients with type 2 diabetes mellitus or metabolic syndrome typically exhibit atherogenic mixed dyslipidemia characterized by low levels of high-density lipoprotein cholesterol, elevated triglycerides, and an increase i...
Current treatment guidelines recommend lowering elevated low-density lipoprotein (LDL) cholesterol levels with a statin as the primary, lipid-modifying intervention to reduce cardiovascular risk in patients with type 2 d...
Clinical guidelines highlight the importance of managing atherogenic mixed dyslipidemia to reduce the risk of premature cardiovascular disease in type 2 diabetes mellitus and metabolic syndrome. The lipid-modifying activ...
The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study provides an extensive evidence base for the efficacy and tolerability of fenofibrate treatment in patients with type 2 diabetes mellitus, predomin...
Even with optimal statin therapy, many patients with type 2 diabetes mellitus or metabolic syndrome fail to achieve all lipid targets and remain at high risk of cardiovascular events. Add-on lipid-modifying therapy that ...